Kate Legge Archives | Page 4 of 4

Merck and Pfizer pneumococcal conjugate vaccine settlement prolongs uncertainty regarding Australian product claims

by Naomi Pearce | Oct 6, 2021 | Blog, Kate Legge, Naomi Pearce, Patents

Recently, Merck Sharp & Dohme (MSD) (known as Merck & Co., Inc. in the US and Canada) announced a settlement and licence agreement with Pfizer Inc. in relation to MSD’s pneumococcal conjugate vaccine (PCV) products, including VAXNEUVANCETM (Pneumococcal...

Wrinkle for supplier of Botox ‘alternative’ as Court finds trade mark infringed, Australian Consumer Law breached

by Naomi Pearce | Sep 27, 2021 | Blog, Kate Legge, Naomi Pearce

The Full Federal Court has held a supplier of cosmetic products (Self Care) liable to Allergan for infringing its BOTOX trade mark and for misleading or deceptive conduct. In doing so, the Court reached novel conclusions as to circumstances in which the comparative...

PTEs in Australia – more hard lessons for patentees from the Federal Court

by Naomi Pearce | Aug 18, 2021 | Blog, Kate Legge, Naomi Pearce, Patents, PTE

The Australian Federal Court has confirmed in Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2021] FCA 947 that, when a patent covers two pharmaceutical substances of the patentee, a patent term extension (PTE) application must be based on the pharmaceutical...

To waive or not to waive: that is the question

by Kate Legge | May 12, 2021 | Blog, Kate Legge

IP waivers alone are nowhere near enough to increase COVID-19 vaccine access for developing countries, but US support for such waivers will create enormous pressure on existing manufacturers to consider how they can do more to facilitate timely access to medicines....

The COVID-19 pandemic prioritises an Australian medical products’ manufacturing road map

by Kate Legge | Mar 25, 2021 | Blog, Kate Legge

Background In October 2020, the Australian Government announced a $1.5 billion investment in a Modern Manufacturing Strategy (MMS) to help Australian manufacturers become more competitive, resilient and build scale in the global market. Specifically, the Government...